FDA studying link between Singulair and suicides
March 31, 2008
The Food & Drug Administration has sent an early communication to healthcare professionals and patients that it is investigating a link between Merck?s Singulair (montelukast) and suicidality. The leukotriene receptor antagonist is used to treat asthma, the symptoms of allergic rhinitis, and to prevent exercise-induced asthma. FDA said it may take up to nine months before it completes its investigation. The agency added that it is also reviewing postmarketing reports of mood changes associated with other leukotriene receptors, such as zafirlukast (Accolate, AstraZeneca) and zileuton (Zyflo and Zyflo CR, Critical Therapeutics).
Article: Judy Chi, DrugTopics
Comments
Got something to say?
Powered by WordPress
